Study type

Study topic

Human medicinal product

Study type

Non-interventional study

Scope of the study

Effectiveness study (incl. comparative)

Data collection methods

Primary data collection
Non-interventional study

Non-interventional study design

Cross-sectional
Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(L02AE02) leuprorelin
leuprorelin
Population studied

Short description of the study population

Groups of health care professionals (HCPs) receiving Dear Healthcare Provider Communication (DHPC) who typically reconstitute and/or administer and/or dispense Eligard®/Depo-Eligard® to patients or healthcare professionals.

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

0
Study design details

Main study objective

1) To measure the awareness of and participation in the Eligard®/Depo-Eligard® RM activities addressing the potential risk of lack of clinical efficacy due to incorrect reconstitution of the product2) To measure HCP knowledge of a potential risk of lack of efficacy due to incorrect reconstitution process of Eligard®/Depo-Eligard®.

Data analysis plan

Process Indicators -- Percentage of respondents that recall: receiving the DHPC, reading the DHPC. Percentage of respondents that recall: receiving additional educational materials, reading or viewing additional educational materials, awareness of additional RM activities, participating in additional RM activities. Outcome Indicators -- Overall knowledge level of each target group, calculated as the mean of individual knowledge scores in that group, The percentage of correct responses for each knowledge question for each target group.